Association of Weight Loss and Medication Adherence Among Adults With Type 2 Diabetes Mellitus: SHIELD (Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes)  by Grandy, Susan et al.
Current Therapeutic Research 75 (2013) 77–82Contents lists available at ScienceDirectCurrent Therapeutic Research0011-39
http://d
n Add
21111.
E-mjournal homepage: www.elsevier.com/locate/cuthreAssociation of Weight Loss and Medication Adherence Among Adults
With Type 2 Diabetes Mellitus: SHIELD (Study to Help Improve Early
evaluation and management of risk factors Leading to Diabetes)
Susan Grandy, PhD1, Kathleen M. Fox, PhD2,n, Elise Hardy, MD1, for the SHIELD Study
Group
1 AstraZeneca LP, Wilmington, Delaware
2 Strategic Healthcare Solutions, LLC, Monkton, Marylanda r t i c l e i n f o
Article history:
Accepted 28 June 2013
Background: Adherence to prescribed diabetes medications is suboptimal, which can lead to poor
glycemic control and diabetic complications. Treatment-related weight gain is a side effect of some oralKey words:
medication adherence
sulfonylurea
thiazolidinedione
type 2 diabetes
weight loss3X & 2013. The Authors. Published by Elsevie
x.doi.org/10.1016/j.curtheres.2013.06.004
ress correspondence to: Kathleen M. Fox, PhD
ail address: kathyfox@gforcecable.com (K.M. Fa b s t r a c t
antidiabetic agents and insulin, which may negatively affect adherence to therapy.
Objective: This study investigated whether adults with type 2 diabetes mellitus (T2DM) who lost weight
had better medication adherence than those who gained weight.
Methods: Weight change over 1 year (2007 to 2008) was assessed among respondents in the US Study to
Help Improve Early evaluation and management of risk factors Leading to Diabetes (SHIELD). Weight loss
of 41.0%, Z3%, and Z5% of weight was compared with weight gain of Z1.0%. Medication adherence
was assessed using the Morisky 4-item questionnaire for medication-taking behavior, with lower scores
representing better adherence.
Results: There were 746 T2DM respondents who lost 41.0%, 483 who lost Z3%, 310 who lost Z5%, and
670 who gained Z1.0% of weight. Each weight-loss group had signiﬁcantly lower Morisky scores than
the weight-gain group; mean scores of 0.389 versus 0.473 (P ¼ 0.050) for the 41.0% weight-loss group,
0.365 versus 0.473 (P ¼ 0.026) for the Z3% weight-loss group, and 0.334 versus 0.473 (P ¼ 0.014) for
the Z5% weight-loss group. Signiﬁcantly fewer respondents who lost weight had received insulin,
sulfonylurea, or thiazolidinedione therapy (57%) compared with respondents who gained weight (64%)
(P ¼ 0.002). Demographics, exercise habits, and dieting were similar between weight-loss and weight-
gain groups.
Conclusions: T2DM respondents with weight loss had signiﬁcantly better medication adherence and
were less likely to be on treatment regimens that increase weight than T2DM respondents with weight
gain. These ﬁndings suggest that strategies that lead to weight loss, including use of diabetes medications
associated with weight loss, may improve medication adherence.
& 2013. The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Patient adherence to prescribed therapies in type 2 diabetes
mellitus (T2DM) including lifestyle changes and medications, is
of substantial importance. With the large and increasing number
of patients affected by T2DM and the associated disease and
economic burden to patients, payers, and employers,1,2 there is ar Inc.
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ox).
Open access under CC BY-NC-ND liceneed to improve outcomes and reduce costs. Among patients with
type 2 diabetes, adherence to prescribed medications has been
reported to be 60% or lower, indicating that many patients are not
following the treatment plan and receiving the full clinical beneﬁt
of the therapies.3–5 Poor adherence can compromise safety and
treatment effectiveness, leading to increased mortality and mor-
bidity.6,7 Conversely, better medication adherence would promote
better outcomes. Improvement in adherence has been shown to
improve glycemic control3,8; in 1 study, glycated hemoglobin
(HbA1c) was reduced by 0.34% for every 25% increase in medi-
cation adherence.9 In a study of 301 patients, good adherence
assessed by the Morisky survey was associated with a 10% lower
HbA1c adjusted for patient demographics and clinical character-
istics.10 Greater medication adherence was associated with lower
rates of hospitalization and lower health care costs.11 One studynse.
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every 10% increase in medication possession ratio.12 In a US
sample of patients with T2DM from 2005 to 2008, improved
adherence was associated with 13% lower odds of subsequent
hospitalizations or emergency department visits, which projected
to averting 699,000 emergency department visits and 341,000
hospitalizations annually, for a savings of $4.7 billion.13 Adherent
employees with diabetes had between 1.7 and 7.1 fewer days
absent from work and between 1.1 and 5.0 fewer days on short-
term disability in a health care claims study.14
The majority of patients with T2DM are overweight or obese,15,16
and increased weight has been shown to worsen glycemic control
and increase the risk of diabetes progression.17,18 Additionally,
weight loss has been shown in large clinical trials to signiﬁcantly
improve glycemic control and lower the risk of progression of
T2DM.16,19,20 Results from studies have shown that as little as a
1 kg or 1% weight loss can have a substantial beneﬁt for glycemic
control, morbidity, and mortality.16,19,21 Mean 1-year total health
care cost was found to be lower for “nonweight gain” patients
($5541) than for patients with weight gain ($7260), with 1 percent-
age point of weight loss associated with a 3.6% decrease in total
health care cost and a 5.8% decrease in T2DM-related cost.22
However, treatment-related weight gain is a side effect of some
oral antidiabetic agents and insulin. Randomized clinical trials
have shown that treatment with insulin, thiazolidinediones
(TZDs), and sulfonylureas (SUs) caused weight gain.23–26 In con-
trast, treatment with glucagon-like peptide 1 (GLP-1) receptor
agonists and metformin result in weight loss.25–28 The Diabetes
Prevention Program (a randomized, double-blind trial of metfor-
min vs. placebo) found that weight loss while on metformin
therapy was related to better adherence to therapy, an effect that
was durable for at least 10 years of treatment.28 However, it is
unknown whether weight change has an impact on medication
adherence among patients with T2DM outside of a clinical trial
setting. The objective of this study was to investigate whether
adults with T2DM treated in routine clinical practice who lost
weight had better medication adherence than those who gained
weight.Methods
The present investigation is an analysis of data from SHIELD
(Study to Help Improve Early evaluation and management of risk
factors Leading to Diabetes) assessing the relationship between
weight loss and adherence to antidiabetic medications. SHIELD is
a 5-year, survey-based study conducted to better understand
patterns of health status, health behavior, and quality of life of
people living with diabetes and those with varying levels of car-
diometabolic risk.
SHIELD Survey
SHIELD included an initial screening phase to identify cases of
interest in the general adult population (eg, diabetes mellitus), a
baseline survey to follow identiﬁed cases with a questionnaire
about health status, health knowledge and attitudes, and current
behaviors and treatments, and annual follow-up surveys for
5 years. A detailed description of the SHIELD methodology was
published previously.29,30
In brief, the screening survey was mailed in April 2004 to a
stratiﬁed random sample of 200,000 US households, representa-
tive of the US population for geographic residence, household size
and income, and age of the head of household,31 identiﬁed by the
Taylor Nelson Sofres National Family Opinion panel (Greenwich,
Conn). All Taylor Nelson Sofres National Family Opinion surveyswere voluntary, and no special incentives were provided. A
response rate of 64% (128,000 households with data on 211,097
individuals) was obtained for the screening survey. SHIELD was
approved by the Quorum Review Board.
A comprehensive baseline survey was mailed in September
through October 2004 to a representative sample of adults (N ¼
22,001) who were identiﬁed in the screening survey as having self-
reported type 1 diabetes mellitus or T2DM, no diabetes, or being at
risk for diabetes. Each respondent group was balanced to be
representative of that segment of the population for age, sex,
geographic region, household size, and income for the US popula-
tion, and then a random sample from each group was selected and
sent the baseline survey. A response rate of 72% was obtained for the
baseline survey. The 2007 and 2008 annual follow-up surveys had
a response rate of 69% and 71%, respectively. Data obtained from the
2008 survey and weight from the 2007 survey were analyzed and
reported in this study for respondents with T2DM.
Study measures
Respondents were classiﬁed as having T2DM based on their
self-report of having been told by a doctor, nurse, or other health
care professional that they had T2DM. Weight and height were
self-reported at the time of the 2007 and 2008 surveys, and body
mass index (BMI) was calculated. Weight change was computed by
subtracting the weight reported in the 2007 survey from the
weight reported in the 2008 survey. Three weight-loss categories
(loss of 41%, Z3.0%, and Z5.0%) were evaluated to determine
whether a small amount of weight loss (41%) was associated with
medication adherence as well as greater weight loss (Z3.0% and
Z5.0%). One weight gain category (41.0%) was used because
previous studies indicated that any weight gain is detrimental to
health.17–19 Previous studies demonstrated that weight changes of
1% and 5% are important for morbidity and mortality.16,19,21,32
Overweight was deﬁned as BMI of 25.0 to 29.9 kg/m2, and obese
was deﬁned as BMI Z30 kg/m2.
The Morisky survey was used to measure patient adherence to
medications in 2008. The Morisky survey is a 4-item questionnaire
with yes/no responses for (1) ever forget to take the medicine,
(2) careless at times about taking the medicine, (3) stop taking
medicine sometimes when you feel better, and (4) stop taking
medicine sometimes if you feel worse.33 A no response was scored
as 0 and a yes response was 1 point. Scores range from 0 to 4, with
higher scores indicating poor adherence. The Morisky scale has
been validated and found to be reliable in a variety of medication
adherence studies.10,33–35 A Morisky score was calculated for each
antidiabetic medication reported by the respondent in 2008. For
respondents receiving Z2 antidiabetic medications, the mean
Morisky score was calculated.
Two drug groups were deﬁned based on the weight association
for each antidiabetic drug class: (1) drugs associated with weight
loss, including GLP-1 receptor agonists and metformin and
(2) drugs associated with weight gain, including TZDs, insulin,
and SUs. Respondents who received a diabetes treatment regimen
with 41 antidiabetic drug that included any weight-gain drug
(TZDs, insulin, SUs) were grouped into the weight-gain drug group
regardless of other antidiabetic drugs (GLP-1 receptor agonists,
metformin, dipeptidyl peptidase-4 [DPP-4] inhibitors) in that
treatment regimen. Respondents who received a DPP-4 inhibitors
and no other antidiabetic drug (monotherapy) were not included
in the analysis of adherence by drug group because DPP-4
inhibitors are weight neutral.16
Exercise habits were determined by the survey question that
asked respondents to choose “the following statement that best
describes your current exercise routine”: “I currently exercise
regularly,” “I currently exercise some, but not regularly,” or
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using the International Physical Activity Questionnaire.36 The
International Physical Activity Questionnaire scores are catego-
rized into 3 levels: (1) low or inactive, (2) moderate activity of
at least Z3 days of vigorous activity of at least 20 minutes per day
or Z5 days of moderate activity or walking of at least 30 minutes
per day, and (3) high activity of a minimum of vigorous activity on
at least 3 days or 7 days of any combination of walking, moderate
or vigorous activities. For diet and eating habits, respondents were
asked whether they had or had not followed any diet plans in the
past 6 months, including the following: therapeutic lifestyle diet,
Mediterranean diet, Atkins diet, South Beach diet, Weight Watch-
ers, vegetarian/vegan diet, other low-fat, high-complex carbohy-
drate diet, other low-carbohydrate diet, or other low-calorie diet.
Respondents were also asked “how many times a week do you
usually eat at a fast food restaurant?”Statistical analysis
The proportion of respondents who lost weight (41.0%,
Z3.0%, Z5.0%) or gained weight (41.0%) from 2007 to 2008
was computed for respondents with T2DM. Respondents who had
71.0% weight change (weight neutral) were excluded from the
analysis, as the association with medication adherence was
expected to be negligible. Comparisons between T2DM respond-
ents who lost weight and those who gained weight were made
using χ2 tests for categorical variables and t tests for continuous
variables. The power analysis indicated that with an α ¼ 0.05,
power ¼ 0.80, and P ¼ 0.50, the minimum detectable effect size
was 0.133 for a sample size of 1400 subjects (41.0% weight loss),
0.147 for sample size of 1150 (Z3.0% weight loss), and 0.159 for
sample size of 980 (Z5.0% weight loss). Linear regression with
Morisky score as the dependent variable and age, sex, race,
education, income, exercise, diet plan, overweight/obese, weight
loss group, and drug group as independent variables were used toTable I
Characteristics of respondents with type 2 diabetes mellitus who lost or gained weight
Characteristic 41.0% Weight Loss
(n ¼ 746)
Age, y, mean (SD) 64.7 (11.8)
Women 62.3
White 71.7
Hispanic heritage 7.0
Education, high school degree or less 36.5
Household income, o$30,000 39.5
Single-member household 31.0
Exercise habits
Currently exercises regularly 24.3
Currently exercises some but not regularly 38.9
Does not currently exercise 36.8
International Physical Activity Questionnaire
Inactive 63.5
Minimally active 23.4
Highly active 13.1
Followed diet plan 31.2
Eat at fast food restaurant Z2 times/wk 23.0
Body mass index category
Normal weight (o25.0 kg/m2) 14.8
Overweight (25.029.9 kg/m2) 24.6
Obese (Z30.0 kg/m2) 60.6
Mean (SD) 33.2 (8.3)
Antidiabetic drug group
TZD, insulin, and/or SU 72.5
GLP-1 receptor agonist and/or metformin 27.5
GLP-1, glucagon-like peptide-1; SU, sulfonylurea; TZD, thiazolidinedione.
nUnless indicate otherwise, values shown are percentages.
†P o 0.05 for comparison of weight loss (41.0%) versus weight gain (41.0%); 1 lbtest the association with Morisky scores. Statistical signiﬁcance
was set a priori as P o 0.05.Results
Among respondents with T2DM who completed the 2007 and
2008 SHIELD surveys, 746 respondents lost 41.0% in weight, 483
lost Z3.0%, 310 lost Z5.0% and 670 respondents gained 41.0%
in weight. Each of the weight-loss cohorts was statistically similar
to the weight-gain cohort in sex, race, education, household
income, household composition, exercise habits, physical activity
level, and diet habits (Table I). The weight-loss cohorts were 1.5 to
2.7 years older than the weight-gain cohort (P o 0.001), and the
weight-loss cohorts had a lower BMI and fewer obese individuals
than the weight-gain cohort (P o 0.001). With regard to anti-
diabetic medications, 411 respondents (21.9%) received only
weight-lowering drugs (GLP-1 receptor agonist, metformin), and
1449 (77.4%) received weight-gain drugs (13 respondents received
DPP-4 monotherapy). Among respondents who lost weight and
received weight-lowering antidiabetic drugs, 91% received metfor-
min monotherapy, 1% received GLP-1 receptor agonist monother-
apy, and 8% received metformin and GLP-1 receptor agonist
combination therapy. For respondents who gained weight and
received weight-gain diabetes drugs, 33.5% received monotherapy
(TZD, insulin, or SU) and 50% received metformin or a GLP-1
receptor agonist in combination with TZD, insulin, or SU. More
respondents in the weight-loss groups (24%28%) received anti-
diabetic medications that were associated with weight loss (met-
formin and/or GLP-1 receptor agonist) than respondents in the
weight-gain group (19%) (P o 0.01). Conversely, more respond-
ents in the weight-gain group (81%) received antidiabetic medi-
cations that were associated with weight gain (TZDs, insulin, SUs)
than respondents in the weight-loss groups (73%76%).
For each of the 3 weight-loss cohorts, mean Morisky scores
were lower, indicating better adherence, than the Morisky scores.*
Z3.0% Weight Loss
(n ¼ 483)
Z5.0% Weight Loss
(n ¼ 310)
41.0% Weight Gain
(n ¼ 670)
64.8 (12.1) 63.6 (12.3) 62.1 (11.1)†
64.6 66.5 61.8
71.8 72.9 72.4
7.7 7.7 5.8
37.3 39.2 32.4
42.0 44.8 33.7
33.1 31.9 29.3
25.0 26.6 23.5
37.6 38.0 40.7
37.4 35.4 35.8
62.7 62.0 66.1
25.1 23.3 22.0
12.2 14.8 11.9
31.5 32.3 28.5
21.7 22.9 28.0
†
17.1 16.6 6.0
24.4 26.4 22.4
58.5 57.0 71.5
33.1 (8.7) 33.2 (8.9) 35.6 (8.3)†
†
73.8 75.9 80.9
26.2 24.1 19.1
¼ 0.4536 kg.
Table II
Morisky scores in 2008 for respondents with type 2 diabetes by weight change.
Morisky Score Weight Loss, % Weight Gain, % P
41.0 41.0
No. 661 601
Mean (SD) 0.389 (0.727) 0.473 (0.803) 0.050
≥3.0 >1.0
No. 426 601
Mean (SD) 0.365 (0.714) 0.473 (0.803) 0.026
≥5.0 >1.0
No. 277 601
Mean (SD) 0.334 (0.721) 0.473 (0.803) 0.014
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who lost 41.0% in weight, the mean Morisky score difference
trended toward statistical signiﬁcance (P ¼ 0.050), whereas the
difference was statistically signiﬁcant for those who lost greater
amounts of weight (P ¼ 0.026 for weight loss Z3.0% and P ¼
0.014 for weight loss Z5.0%). There was a decrease in Morisky
scores as weight loss increased: 0.389 for the 41.0% weight-loss
cohort to 0.334 for the Z5.0% weight-loss cohort.
Morisky scores were lower (better adherence) among T2DM
respondents who lost weight and received TZDs, insulin, or SUs
compared with T2DM respondents who gained weight and
received TZDs, insulin, or SUs (Table III). The difference in Morisky
scores among respondents who received TZDs, insulin, or SUs was
statistically signiﬁcant (P o 0.05) for each of the 3 weight-loss
groups versus the weight-gain group. T2DM respondents who lost
weight and received a GLP-1 receptor agonist or metformin had
lower Morisky scores (better adherence) than T2DM respondents
who gained weight and received a GLP-1 receptor agonist or
metformin, but the difference was not signiﬁcant (P 4 0.10).
A linear regression model adjusting for age, sex, race, educa-
tion, income, exercise, diet plan, overweight/obese, and drug
group found that Morisky scores were negatively associated
(better adherence) with receiving weight-loss antidiabetic drugs
in the respondents with 41% weight loss (P ¼ 0.002) and
respondents with Z3.0% weight loss (P ¼ 0.004) but not among
respondents with Z5% weight loss (P ¼ 0.08) (Table IV). Weight
loss of Z3% and Z5% compared with weight gain was signiﬁ-
cantly associated with lower Morisky scores after adjustment.Discussion
In this population-based study, each weight-loss cohort had
better antidiabetic medication adherence compared with the
weight-gain cohort. Even a small weight loss of 41% was
associated with a positive impact on medication adherence, andTable III
Morisky scores in 2008 for respondents with type 2 diabetes by weight change and di
Drug Group 41.0% Weight
Loss
Z3.0% Weight
Loss
Z
L
Weight-gain drugs: TZD, insulin, and/or SU
No. 470 307
Morisky score, mean (SD) 0.338 (0.673) 0.311 (0.646) 0
Weight-loss drugs: GLP-1 receptor agonist and/
or metformin
No. 185 115
Morisky score, mean (SD) 0.530 (0.841) 0.522 (0.862) 0
GLP-1, glucagon-like peptide-1; SU, sulfonylurea; TZD, thiazolidinedione.the association with medication adherence was greater with
greater weight loss. Signiﬁcantly fewer respondents who lost
weight had received antidiabetic medications that caused weight
gain (TZDs, insulin, SUs) compared with respondents who gained
weight, and adherence was better (lower Morisky scores) among
respondents who lost weight and received antidiabetic drugs that
caused weight gain (TZDs, insulin, SUs) compared with respond-
ents who gained weight and received TZDs, insulin, or SUs. Other
factors that were assessed did not explain the association between
weight loss and better medication adherence, as the weight-loss
cohorts were similar to the weight-gain cohort for demographics,
exercise, physical activity, and dieting and eating habits.
There appeared to be a “dose response” to weight loss and
better medication adherence. Small amounts of weight loss (41%)
were associated with better medication adherence, and Z5% loss
of weight had a stronger association with improved medication
adherence. The 41% weight-loss cohort had, on average, a 17.8%
better adherence score than the weight-gain cohort, whereas the
Z3% and Z5% weight-loss cohorts had 22.8% and 29.4% better
adherence scores than the weight-gain cohort, respectively. Addi-
tionally, medication adherence was better (lower scores) as weight
loss increased among those who received antidiabetic drugs that
cause weight gain and among those who received only metformin
and/or a GLP-1receptor agonist. These ﬁndings provide further
evidence of the importance of managing weight in the overall
disease management of diabetes. As previous studies showed that
better medication adherence improves glycemic control,3,8–10
it would be expected that the T2DM respondents in the present
study who lost weight and had better medication adherence
would also have better glycemic control. Using the 0.34% reduction
in HbA1c for every 25% increase in medication adherence from the
Rhee et al study,9 it is possible that the Z3% and Z5% weight-loss
cohorts could be expected to have 0.34% lower HbA1c than the
weight-gain cohort. The SHIELD did not collect HbA1c levels from
the respondents, so the actual glycemic control could not be
assessed. The respondents who lost weight and had better
medication adherence would also be expected to have lower rates
of hospitalization and lower health care costs based on the
ﬁndings of other studies.11–13
Other factors in addition to weight change for certain anti-
diabetic drugs may affect medication adherence. Certain antidia-
betic drugs are associated with a higher rate of hypoglycemia, and
GLP-1 drugs and insulin are injectables, which may adversely
affect medication adherence. The side effects of antidiabetic drugs
and the severity of diabetes were not captured in the SHIELD so
they could not be evaluated in the present study.
The ﬁndings of the present study are similar to the ﬁndings in
the Diabetes Prevention Program, which also showed better
adherence to therapy among patients who lost weight.28 In the
long-term follow-up analysis of the Diabetes Prevention Program,abetes drug group.
5.0% Weight
oss
41.0% Weight
Gain
P for Weight Loss Versus Weight Gain
206 483
.303 (0.660) 0.432 (0.775) 0.048 for 41.0% loss, 0.023 for Z3.0% loss, 0.038
for Z5.0% loss
68 114
.441 (0.887) 0.658 (0.901) 0.21 for 41.0% loss, 0.24 for Z3.0% loss, 0.12 for
Z5.0% loss
Table IV
Linear regression coefﬁcients for Morisky score adjusted for demographic and lifestyle characteristics.
Weight loss 41.0% Weight loss Z3.0% Weight loss Z5.0%
β Coefﬁcient P β Coefﬁcient P β Coefﬁcient P
Weight-loss drug vs. weight-gain drug 0.167 0.002 0.172 0.004 0.118 0.081
Age (continuous) 0.017 o0.0001 0.018 o0.0001 0.019 o0.0001
Male vs. female 0.006 0.90 0.020 0.71 0.015 0.80
Black vs. white 0.160 0.005 0.150 0.017 0.199 0.003
Other race vs. white 0.193 0.058 0.276 0.014 0.215 0.097
College or graduate courses vs. high school or less 0.051 0.32 0.146 0.009 0.135 0.029
Income, $
35,000–49,000 vs. o35,000 0.045 0.46 0.011 0.87 0.007 0.92
50,000–74,000 0.020 0.77 0.047 0.51 0.030 0.71
Z75,000 0.087 0.20 0.160 0.030 0.219 0.008
Exercise regularly (yes/no) 0.105 0.033 0.178 0.001 0.186 0.002
Diet plan in past 6 mo (yes/no) 0.103 0.074 0.117 0.064 0.145 0.038
Tried to lose weight (yes/no) 0.063 0.22 0.063 0.267 0.067 0.28
Overweight vs. normal weight 0.049 0.58 0.021 0.83 0.054 0.63
Obese vs. normal weight 0.071 0.40 0.005 0.96 0.022 0.84
Lost vs. gained weight 0.032 0.16 0.051 0.049 0.067 0.027
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those receiving placebo, and the magnitude of weight loss was
directly related to continuing medication adherence.28 Similar to
these ﬁndings from the Diabetes Prevention Program, the present
study found that adherence was better among respondents who
lost weight and received metformin and/or a GLP-1 receptor
agonist compared with respondents who gained weight and
received metformin and/or a GLP-1 receptor agonist.
Weight change in the present study was similar to that in other
studies. A retrospective study of adults with T2DM from a health
maintenance organization by Yu et al22 found that 48.9% of
patients experienced weight gain (minimum of 1 pound), and
the present study found that 47.3% of study population had 41%
weight gain. Also, Yu et al22 found that the weight-gain group had
signiﬁcantly higher use of TZDs than the group without weight
gain, a ﬁnding similar to that in the present study.
The present study used a large, population-based sample of
T2DM respondents to assess the association of weight change on
medication adherence. There are limitations to the study that
should be considered. Information about glycemic control (HbA1c)
was not collected in the SHIELD survey, so the impact of improved
adherence with weight loss on glycemic control could not be
investigated. The determination of T2DM and weight was made
based on self-report rather than on clinical or laboratory measures.
However, this determination was made consistently for all
respondent groups evaluated in this study, so it should not have
affected the comparison across groups. Household panels, like the
SHIELD, tend to underrepresent the very wealthy and very poor
segments of the population and do not include military or
institutionalized individuals. These limitations are true for most
random sampling and clinically based methodologies. Self-
selection bias may be present because respondents were those
who could read and comprehend the survey.Conclusions
Adults with T2DM and weight loss had signiﬁcantly better
medication adherence and were less likely to be on treatment
regimens that increase weight than adults with T2DM and weight
gain. Based on current diabetes treatment patterns seen in this
study, a majority of patients may receive treatment regimens that
increase weight. Therefore, consideration of the weight change
characteristics of an antidiabetic agent is important when managing
patients with T2DM, especially those with obesity. Communicatingthe beneﬁts of at least 1% reduction in weight on medication
adherence, glycemic control, and reduced morbidity and mortality
to patients may be an effective approach to diabetes management.Acknowledgments
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